Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $1.45 billion. The enterprise value is $923.67 million.
| Market Cap | 1.45B |
| Enterprise Value | 923.67M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 68.95 million shares outstanding. The number of shares has increased by 34.84% in one year.
| Shares Outstanding | 68.95M |
| Shares Change (YoY) | +34.84% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 5.77% |
| Owned by Institutions (%) | 92.18% |
| Float | 46.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.27, with a Debt / Equity ratio of 0.05.
| Current Ratio | 29.27 |
| Quick Ratio | n/a |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -47.97 |
Financial Efficiency
Return on equity (ROE) is -29.70% and return on invested capital (ROIC) is -30.81%.
| Return on Equity (ROE) | -29.70% |
| Return on Assets (ROA) | -27.20% |
| Return on Capital (ROIC) | -30.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.71M |
| Employee Count | 56 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.29% in the last 52 weeks. The beta is -0.38, so AKRO's price volatility has been lower than the market average.
| Beta (1Y) | -0.38 |
| 52-Week Price Change | -53.29% |
| 50-Day Moving Average | 24.69 |
| 200-Day Moving Average | 29.20 |
| Relative Strength Index (RSI) | 35.31 |
| Average Volume (30 Days) | 1,396,129 |
Short Selling Information
The latest short interest is 7.84 million, so 11.38% of the outstanding shares have been sold short.
| Short Interest | 7.84M |
| Short Previous Month | 9.47M |
| Short % of Shares Out | 11.38% |
| Short % of Float | 17.02% |
| Short Ratio (days to cover) | 3.59 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.87M |
| Pretax Income | -151.76M |
| Net Income | -151.76M |
| EBITDA | -148.40M |
| EBIT | -148.66M |
| Earnings Per Share (EPS) | -$2.89 |
Balance Sheet
The company has $550.01 million in cash and $25.78 million in debt, giving a net cash position of $524.23 million or $7.60 per share.
| Cash & Cash Equivalents | 550.01M |
| Total Debt | 25.78M |
| Net Cash | 524.23M |
| Net Cash Per Share | $7.60 |
| Equity / Book Value | 535.31M |
| Book Value Per Share | 7.76 |
| Working Capital | 540.83M |
Cash Flow
| Operating Cash Flow | -145.37M |
| Capital Expenditures | n/a |
| Free Cash Flow | -145.37M |
| FCF Per Share | -$2.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AKRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.84% |
| Shareholder Yield | -34.84% |
| Earnings Yield | -10.48% |
| FCF Yield | -10.04% |
Analyst Forecast
The average price target for AKRO is $44.25, which is 110.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.25 |
| Price Target Difference | 110.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |